Trials / Unknown
UnknownNCT04025593
Biomarker Guided Treatment in DLBCL
A Randomized, Phase 2 Study of Biomarker Guided Treatment in DLBCL
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 128 (estimated)
- Sponsor
- Ruijin Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study is to investigate the strategy of biomarker guided treatment in diffuse large B cell lymphoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cyclophosphamide | 750mg/m2 day 1 |
| DRUG | Rituximab | 375mg/m2 day 0 |
| DRUG | Doxorubicin | 50mg/m2 day 1 |
| DRUG | Vincristine | 1.4mg/m2, max 2mg day 1 |
| DRUG | Prednisone | 60mg/m2, max 100mg day 1-5 |
| DRUG | Ibrutinib | 420mg/day qd |
| DRUG | Lenalidomide | 25mg day1-10 |
| DRUG | chidamide | 20mg day 1,4,8,11 |
| DRUG | decitabine | decitabine 10mg/m2 day-5 to day-1 |
Timeline
- Start date
- 2019-07-17
- Primary completion
- 2021-07-01
- Completion
- 2023-06-01
- First posted
- 2019-07-19
- Last updated
- 2020-11-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04025593. Inclusion in this directory is not an endorsement.